

Table 1. Overview of TEAEs and most common TEAEs (occurring in ≥ 2 patients) in patients with POS by first and second monotherapy use at baseline (Safety Analysis Set)

	First monotherapy (n=93)	Second monotherapy (n=9)
Any TEAE, n (%)	70 (75.3)	7 (77.8)
Most common TEAEs (≥ 2 patients), n (%)		
Dizziness	48 (51.6)	3 (33.3)
Somnolence	9 (9.7)	1 (11.1)
Headache	9 (9.7)	0 (0.0)
Dysarthria	5 (5.4)	0 (0.0)
Seizure	3 (3.2)	0 (0.0)
Anger	2 (2.2)	0 (0.0)
Edema	2 (2.2)	0 (0.0)
Fatigue	2 (2.2)	0 (0.0)
Memory impairment	2 (2.2)	0 (0.0)
Pruritus	2 (2.2)	0 (0.0)
Serious TEAEs, n (%)	6 (6.5)	2 (22.2)
TEAEs leading to discontinuation, n (%)	13 (14.0)	1 (11.1)

POS, partial-onset seizures; TEAE, treatment-emergent adverse event